Le Lézard
Classified in: Covid-19 virus
Subjects: Conference, Event, Webcast

STAAR Surgical Company to Hold 2020 Annual Meeting of Shareholders in Virtual Format


STAAR Surgical Company (NASDAQ: STAA) today announced that to support the health and well-being of its shareholders, employees, directors, and communities due to the public health threat of the COVID-19 pandemic the Company's upcoming 2020 Annual Meeting of Shareholders (the "Annual Meeting") will be held in a virtual-only format. As previously announced, the Annual Meeting will be held on Thursday, July 30, 2020, at 8:30 a.m. PT, but shareholders will not be able to attend in person. The virtual meeting will provide shareholders the ability to participate, vote their shares, and ask questions.

As described in the proxy materials for the Annual Meeting previously distributed, shareholders are entitled to participate in the Annual Meeting if they were a shareholder as of the close of business on June 1, 2020, the record date. Regardless of whether you plan to attend the Annual Meeting, we urge you to vote and submit your proxy in advance of the meeting by one of the methods described in the proxy materials for the Annual Meeting. The proxy card included with the proxy materials previously distributed may continue to be used to vote your shares in connection with the Annual Meeting.

To be admitted to the virtual Annual Meeting, go to www.virtualshareholdermeeting.com/STAA2020 and enter your unique 16-digit control number, which may be found on the proxy card, voting instruction form or Notice of Internet Availability of Proxy Materials, as applicable, provided with STAAR's previously distributed proxy materials. You may vote during the Annual Meeting by following the instructions available on the meeting website during the meeting.

Shareholders as of the record date who attend and participate in the virtual Annual Meeting using their control number (as described above) will have an opportunity to submit questions via the Internet. We will try to answer as many shareholder-submitted questions that comply with the rules of conduct as time permits.

For technical assistance during the meeting, shareholders can contact Broadridge for assistance at 800-586-1548 (U.S.) or 303-562-9288 (international).

Additional information regarding the rules and procedures for participating in the virtual Annual Meeting will be set forth in our meeting rules of conduct, which shareholders can view during the meeting at the meeting website or prior to the meeting at www.proxyvote.com. The proxy statement and Annual Report are available on our Investor Relations website at https:/investors.staar.com/proxy-information/.


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: